STL Volume 27 Number 2

3 POSTS 0 COMMENTS
Purchase PDF for $2.79
image of woman with infected lips, cold sore

Plerixafor on a WHIM – Promise or Fantasy of a New CXCR4 Inhibitor for...

Emerging molecular experimental and clinical data suggests that CXCR4 may play an important role in other skin and systemic diseases including mycosis fungoides/Sézary syndrome, neurofibromatosis type 1 tumors, allergic reactions, Waldenström macroglobulinemia, melanoma, non-melanoma skin cancers and other solid tumors.
image of woman applying cream on psoriasis patch

Transition of Topical Therapy Formulation in Psoriasis: Insights from a Canadian Practice Reflective

The benefits of transitioning from Cal/BD ointment or gel to aerosol foam formulation in this Canadian patient population were similar to those reported in clinical studies and were seen consistently among patients with a range of treatment priorities and with differing history of psoriasis severity and treatment history.
image of woman holding pills and reading instructions

Update on Drugs & Devices: March-April 2022

This update covers Adalimumab biosimilar - Yuflyma™ (Celltrion Healthcare), Adalimumab biosimilar - Simlandi™ (Alvotech/JAMP Pharma), Abrocitinib tablet - Cibinqo® (Pfizer), Upadacitinib tablet - Rinvoq® (AbbVie), Risankizumab-rzaa SC injection - Skyrizi® (AbbVie), and HA-based dermal filler - Juvéderm® Volbella® XC (AbbVie/ Allergan Aesthetics).

POPULAR

Advertisement